0001209191-24-000426.txt : 20240103 0001209191-24-000426.hdr.sgml : 20240103 20240103164756 ACCESSION NUMBER: 0001209191-24-000426 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DiRaimondo Thomas CENTRAL INDEX KEY: 0002005618 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40475 FILM NUMBER: 24507546 MAIL ADDRESS: STREET 1: C/O JANUX THERAPEUTICS, INC. STREET 2: 10955 VISTA SORRENTO PARKWAY, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Janux Therapeutics, Inc. CENTRAL INDEX KEY: 0001817713 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822289112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 751-4493 MAIL ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-02 0 0001817713 Janux Therapeutics, Inc. JANX 0002005618 DiRaimondo Thomas C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130 0 1 0 0 Chief Scientific Officer 0 Stock Option (right to buy) 11.02 2024-01-02 4 A 0 147000 0.00 A 2034-01-01 Common Stock 147000 147000 D 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period. /s/ Maria Dobek, Attorney-in-Fact 2024-01-03